Journal for Immunotherapy of Cancer. 6 (1): 47. doi:10.1186/s40425-018-0356-4. PMC 5987416. PMID 29866156. (Articles with short ...
Immunotherapy is another potential approach. Monoclonal antibodies against Junin virus have been tested in animal models. An ... "Rational design of universal immunotherapy for TfR1-tropic arenaviruses". Nature Communications. 11 (1): 67. Bibcode:2020NatCo ...
Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X (May 2019). "Optimization of 4-1BB antibody for cancer immunotherapy by ... Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE (July 2015). "Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy". ... Journal for Immunotherapy of Cancer. 8 (Suppl 3). doi:10.1136/jitc-2020-SITC2020.0647. S2CID 228992726. (Articles with short ... Urelumab is an innovative and promising cancer immunotherapy. The first phase I trial of Urelumab began in 2006 and final ...
The activation immunotherapies can revive and enhance immune cell function. Comparing to other immunotherapies, therapies ... Broussard, Grant; Damania, Blossom (2020-02-07). "KSHV: Immune Modulation and Immunotherapy". Frontiers in Immunology. 10: 3084 ...
"About". Focused Ultrasound Cancer Immunotherapy Center. Retrieved 2023-01-20. Jackson, Christina (2020-07-15). "Scientists ... and with the School of Medicine's Focused Ultrasound Cancer Immunotherapy Center. UVA Cancer Center's research findings include ...
Journal for Immunotherapy of Cancer. 9 (9): e002647. doi:10.1136/jitc-2021-002647. PMC 8477334. PMID 34580161. Beane JE, ...
"Tumor Immunity and Cancer Immunotherapy". Archived from the original on 2010-08-27. Retrieved 2010-08-25. Medical Immunology, ...
April 2019). "Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy". Nature Medicine. ... Journal for Immunotherapy of Cancer. 5 (1): 53. doi:10.1186/s40425-017-0257-y. PMC 5514481. PMID 28716061. Sankhala KK, Blay J ... and could be a potential therapeutic target for cancer immunotherapy. TAMs have historically been described as falling into two ... "TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy ...
Journal for Immunotherapy of Cancer. 11 (1): e005881. doi:10.1136/jitc-2022-005881. PMC 9835961. PMID 36631162. Raman S, ...
Journal for Immunotherapy of Cancer. 6 (1): 28. doi:10.1186/s40425-018-0339-5. PMC 5905120. PMID 29665849. Qin Y, Wang L, Zhang ...
Immunotherapy aims at ceasing this immune blockage by blocking those receptor ligand pairs. In the case of avelumab, the ... PD-1 itself has also been a target for immunotherapy. Therefore, avelumab belongs to the group of immune checkpoint blockade ... Journal for Immunotherapy of Cancer. 6 (1): 7. doi:10.1186/s40425-017-0310-x. PMC 5774167. PMID 29347993. "FDA approves ...
Peter, Malin; Kühnel, Florian (2020). "Oncolytic Adenovirus in Cancer Immunotherapy". Cancers. 12 (11): 3354. doi:10.3390/ ... Peter, Malin; Kühnel, Florian (2020). "Oncolytic Adenovirus in Cancer Immunotherapy". Cancers. 12 (11): 3354. doi:10.3390/ ... "Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4". Gene ... Prospects for Cancer Immunotherapy". Frontiers in Microbiology. 12: 707290. doi:10.3389/fmicb.2021.707290. PMC 8334181. PMID ...
Immunotherapy with these immune checkpoint inhibitors appears to shrink tumours in a higher number of patients across a wider ... Immunotherapies as a group have off-target effects and toxicities common to them. Some of these include interstitial ... Cancer immunotherapy - Immune checkpoints Intracellular checkpoints - CISH Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, ... In 2017, it became the first immunotherapy drug approved for use based on the genetic mutations of the tumor rather than the ...
The odds of immunotherapy success". Science. 350 (6257): 158-159. Bibcode:2015Sci...350..158G. doi:10.1126/science.aad4140. ... Median OS was 15.6 and 10.9 months, in the immunotherapy-chemotherapy and the chemotherapy only groups, respectively. A Phase 2 ... "Immunotherapy drug combo could combat melanoma". PubMed Health. "Peregrine Pharmaceuticals Announces Initiation of an ... Ribas A (June 2012). "Tumor immunotherapy directed at PD-1". The New England Journal of Medicine. 366 (26): 2517-2519. doi: ...
Journal for Immunotherapy of Cancer. 1 (Suppl 1): P240. doi:10.1186/2051-1426-1-S1-P240. ISSN 2051-1426. PMC 3990302. Peterson ...
Journal for Immunotherapy of Cancer. 9 (9): e002647. doi:10.1136/jitc-2021-002647. PMC 8477334. PMID 34580161. Vlahopoulos SA, ...
Neri, D.; Petrul, H.; Roncucci, G. (August 1995). "Engineering recombinant antibodies for immunotherapy". Cell Biophysics. 27 ( ... and CAR-T Immunotherapy". Cancers. 8 (3): 36. doi:10.3390/cancers8030036. PMC 4810120. PMID 26999211. Albert, Susann; Arndt, ... "Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans". Nature Medicine ...
Huo X, Shen G, Liu Z, Liang Y, Li J, Zhao F, Ren D, Zhao J (December 2021). "Addition of immunotherapy to chemotherapy for ... However, the use of any of these monoclonal antibody drugs as a single immunotherapy agent often benefits only a small ... Ribas A, Wolchok JD (March 2018). "Cancer immunotherapy using checkpoint blockade". Science. 359 (6382): 1350-1355. Bibcode: ... "A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas". Cancers. 12 (7): 1873. doi: ...
Journal for Immunotherapy of Cancer. 8 (2): e000417. doi:10.1136/jitc-2019-000417. ISSN 2051-1426. PMC 7394305. PMID 32727810. ...
Journal for immunotherapy of cancer. 10 (1). doi:10.1136/jitc-2021-003687. PMC 8753443. PMID 35017155. Sherif, S., Roelands, J ... Journal for Immunotherapy of Cancer. 8 (1): e000617. doi:10.1136/jitc-2020-000617. PMC 7223637. PMID 32376723. Bertucci, F; ... immune response has been linked to favorable outcomes with immunotherapy, but not all immunologically active cancers respond to ... clustering of tumours based on ICR gene expression provides an assessment of the prognosis and response to immunotherapy. To ...
Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA (September 2007). "Immunotherapy for Guillain-Barré ... Development of new treatments has been limited since immunotherapy was introduced in the 1980s and 1990s. Current research is ... Liu, Shuang; Dong, Chaoling; Ubogu, Eroboghene Ekamereno (2021-06-02). "Immunotherapy of Guillain-Barré syndrome". Human ... September 2003). "Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee ...
Baecher-Allan, C.; Kaskow, B. J.; Weiner, H. L. (Feb 2018). "Multiple Sclerosis: Mechanisms and Immunotherapy". Neuron. 97 (4 ... potential opportunities for immunotherapy". Clin Transl Immunol. 3 (10): e27. doi:10.1038/cti.2014.25. PMC 4237030. PMID ...
Journal for Immunotherapy of Cancer. 7 (1): 20. doi:10.1186/s40425-019-0510-7. ISSN 2051-1426. PMC 6348630. PMID 30691536. "EMA ...
Journal for Immunotherapy of Cancer. 5 (1): 53. doi:10.1186/s40425-017-0257-y. PMC 5514481. PMID 28716061. The tumor-permissive ...
Type II IFN has played a role in the development of cancer immunotherapy treatments due to its ability to prevent tumor growth ... IFN-γ is not approved yet for the treatment in any cancer immunotherapy. However, improved survival was observed when IFN-γ was ... The goal of cancer immunotherapy is to trigger an immune response by the patient's immune cells to attack and kill malignant ( ... The importance of type II IFN in cancer immunotherapy has been acknowledged; current research is studying the effects of type ...
It was one of the first oncolytic immunotherapy approved globally; it was approved in the US in October 2015 and approved in ... Talimogene laherparepvec is the world's first approved oncolytic immunotherapy, i.e. it was also designed to provide systemic ... "FDA approves Amgen's Injected Immunotherapy for Melanoma". Reuters. 27 October 2015. "Imlygic (talimogene laherparepvec)". U.S ... Journal for Immunotherapy of Cancer. 7 (1): 145. doi:10.1186/s40425-019-0623-z. PMC 6554874. PMID 31171039. Franke V, Berger DM ...
In January 2019, Celgene was acquired by Bristol-Myers Squibb, which is developing a similar cancer immunotherapy drug, Opdivo ... Journal for ImmunoTherapy of Cancer. 8 (1): e000453. doi:10.1136/jitc-2019-000453. ISSN 2051-1426. PMC 7295442. PMID 32540858. ... but is Beigene deal too late for cancer immunotherapy race?". STAT. Retrieved 2020-08-04. Armstrong, Drew (2019-06-17). " ...
TILT Biotherapeutics Ltd "TILT Biotherapeutics Secures 10 M ($10.6M) for Viral Cancer T-Cell Immunotherapy"[permanent dead link ... Akseli Hemminki's research focuses on cancer immunotherapy and especially on oncolytic adenoviruses. The goal of his research ... Hemminki, A. (2014). "Oncolytic Immunotherapy: Where Are We Clinically?". Scientifica. 2014: 1-7. doi:10.1155/2014/862925. PMC ... Hemminki, O.; Hemminki, A. (2015). "A century of oncolysis evolves into oncolytic immunotherapy". Oncoimmunology. 5 (2): ...
PhD, Arthur N. Brodsky (31 October 2019). "PORTER Immunotherapy Clinical Trial Unveiled". Cancer Research Institute. Retrieved ... of California and Foundery Sign Master Agreement to Translate Novel Discoveries into Transformational Immunotherapies". www. ...
Journal for Immunotherapy of Cancer. 7 (1): 263. doi:10.1186/s40425-019-0761-3. PMC 6798508. PMID 31623687. v t e (Articles ...